期刊文献+

肝癌患者肿瘤组织和血清lncRNAs水平变化的研究 被引量:1

Research on changes of lncRNAs levels in tumor tissues and serum in patients with hepatocellular carcinoma
下载PDF
导出
摘要 目的研究肝细胞肝癌(HCC)患者组织和血清中lncRNAs(lncRNA HOTAIR,IncRNA DANCR,IncRNA HOTTIP,IncRNA TCF7)的表达水平。方法采用实时定量PCR方法检测28例肝细胞肝癌(HCC)患者(HCC组)及12例肝血管瘤患者(对照组)组织和血清中IncRNAs HOTAIR、HOTTIP、DANCR和TCF7的表达水平。结果HCC癌组织中IncRNA DANCR和IncRNA TCF7相对表达量明显高于肝血管瘤组织和癌旁组织(P<0.05),IncRNA HOTAIR和IncRNA HOTTIP相对表达量则无明显差异(P〉0.05)。与对照组比较,HCC组血清中IncRNA DANCR和IncRNA HOTTIP表达量显著上调,而IncRNA HOTAIR和IncRNA TCF7表达量则无明显差异(P〉0.05)。血清IncRNA DANCR和IncRNA HOTTIP联合检测诊断HCC的AUC最大为0.929(95%CI:0.808-0.996,P<0.01)。结论肝癌组织IncRNA DANCR和IncRNA TCF7表达水平上调;HCC患者血清IncRNA DANCR和IncRNA HOTTIP表达量显著上调。血清IncRNA HOTTIP和IncRNA DANCR可能是潜在的HCC诊断标志物,有望提高HCC的早期诊断率。 Objective To study the expression of IncRNAs(IncRNA HOTAIR,IncRNA DANCR,IncRNA HOTTIP,IncRNA TCF7)in tissues and serums in patients with hepatocellular carcinoma(HCC).Methods The quantitative real-time PCR method was used to determine the expression levels of IncRNAs HOTAIR,HOTTIP,DANCR and TCF7 in tissues and serums of HCC group(n=28 patients with HCC)and the control group(71=12 patients with hepatic hemangioma).Results The relative expression levels of IncRNA DANCR and IncRNA TCF7 in HCC tissues were significantly higher than that of hepatic hemangioma tissues and para-carcinoma tissues(P<0.05),without significant difference in the relative expression levels of IncRNA HOTAIR and IncRNA HOTTIP(P>0.05).The expression of IncRNA DANCR and IncRNA HOTTIP in HCC group was significantly higher than that in the control group,without significant difference in expression of IncRNA HOTAIR and IncRNA TCF7(P>0.05).The maximum AUC of HCC detected by IncRNA DANCR combined with IncRNA HOTTIP was 0.929(95%CI:0.808-0.996,P<0.01).Conclusion The expression levels of IncRNA DANCR and IncRNA TCF7 in HCC tissues are higher;expression levels of IncRNA DANCR and IncRNA HOTTIP in HCC patients are significantly upregulated.The IncRNA HOTTIP and IncRNA DANCR in serum may be potential diagnostic markers of HCC,which are expected to improve the early diagnostic rate of HCC.
作者 王一涵 冯亚星 刘卫辉 Wang Yihan;Feng Yaxing;Liu Weihui(College of Medicine,Southwest Jiaotong University,Chengdu,Sichuan,610031,China;Center of General Surgery,General Hospital of Western Theater Command,Chengdu,Sichuan,610083,China)
出处 《西南国防医药》 CAS 2019年第10期1004-1007,共4页 Medical Journal of National Defending Forces in Southwest China
基金 国家自然科学基金青年项目(81302168) 四川省应用基础研究重点项目(2019YJ0586)
关键词 肝细胞癌 长链非编码RNA HOTTIP DANCR 诊断 HCC long non-coding RNA HOTTIP DANCR diagnosis
  • 相关文献

参考文献1

二级参考文献115

  • 1Schmieder R, Puehler F, Neuhaus R, Kissel M, Adjei AA, MinerJN, Mumberg D, Ziegelbauer K, Scholz A. Allosteric MEK1/2inhibitor refametinib (BAY 86-9766) in combination with sorafenibexhibits antitumor activity in preclinical murine and rat models ofhepatocellular carcinoma. Neoplasia 2013; 15: 1161-1171 [PMID:24204195 DOI: 10.1593/neo.13812].
  • 2Su JC, Tseng PH, Wu SH, Hsu CY, Tai WT, Li YS, Chen IT,Liu CY, Chen KF, Shiau CW. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation inhepatocellular carcinoma. Neoplasia 2014; 16: 595-605 [PMID:25047655 DOI: 10.1016/j.neo.2014.06.005].
  • 3Xia H, Ooi LL, Hui KM. MicroRNA-216a/217-induced epithelialmesenchymaltransition targets PTEN and SMAD7 to promotedrug resistance and recurrence of liver cancer. Hepatology 2013;58: 629-641 [PMID: 23471579 DOI: 10.1002/hep.26369].
  • 4El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiologyand molecular carcinogenesis. Gastroenterology 2007; 132:2557-2576 [PMID: 17570226 DOI: 10.1053/j.gastro.2007.04.061].
  • 5Sakurai T, Kudo M, Umemura A, He G, Elsharkawy AM, SekiE, Karin M. p38α inhibits liver fibrogenesis and consequenthepatocarcinogenesis by curtailing accumulation of reactiveoxygen species. Cancer Res 2013; 73: 215-224 [PMID: 23271722DOI: 10.1158/0008-5472.can-12-1602].
  • 6Zhang T, Zhang J, Cui M, Liu F, You X, Du Y, Gao Y, ZhangS, Lu Z, Ye L, Zhang X. Hepatitis B virus X protein inhibitstumor suppressor miR-205 through inducing hypermethylation ofmiR-205 promoter to enhance carcinogenesis. Neoplasia 2013; 15:1282-1291 [PMID: 24339740 DOI: 10.1593/neo.131362].
  • 7Qi LN, Bai T, Chen ZS, Wu FX, Chen YY, De Xiang B, PengT, Han ZG, Li LQ. The p53 mutation spectrum in hepatocellularcarcinoma from Guangxi, China : role of chronic hepatitis B virusinfection and aflatoxin B1 exposure. Liver Int 2015; 35: 999-1009[PMID: 24461059 DOI: 10.1111/liv.12460].
  • 8Aravalli RN, Cressman EN, Steer CJ. Cellular and molecularmechanisms of hepatocellular carcinoma: an update. ArchToxicol 2013; 87: 227-247 [PMID: 23007558 DOI: 10.1007/s00204-012-0931-2].
  • 9Shin JW, Chung YH. Molecular targeted therapy for hepatocellularcarcinoma: current and future. World J Gastroenterol 2013; 19:6144-6155 [PMID: 24115810 DOI: 10.3748/wjg.v19.i37.6144].
  • 10Cao C, Sun J, Zhang D, Guo X, Xie L, Li X, Wu D, Liu L. Thelong intergenic noncoding RNA UFC1, a target of MicroRNA 34a,interacts with the mRNA stabilizing protein HuR to increase levelsof β-catenin in HCC cells. Gastroenterology 2015; 148: 415-426.e18 [PMID: 25449213 DOI: 10.1053/j.gastro.2014.10.012].

共引文献18

同被引文献11

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部